The purpose of this study is to determine clinical efficacy and safety of KM110329 for Atopic dermatitis.
A randomized, double blind, placebo-controlled, multicenter trial will be conducted at the Seoul St.Mary's Hospital, at Chung-ang University hospital, and at Kyung Hee University Hospital at Gangdong. Participants fulfilling eligibility criteria will be selected. Enrolled participants will be randomly allocated to two parallel groups: the KM110329 and placebo arms. Each participant will be examined for signs and symptoms of Atopic dermatitis before and after taking functional food.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
66
Kyung Hee University
Seoul, South Korea
RECRUITINGSCORAD index
SCORing Atopic Dermatitis
Time frame: 8 weeks
DLQI
The Dermatology Life Quality Index
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.